NEW-U
RESEARCH COMPOUNDS

CERTIFICATE OF ANALYSIS

new-u.io/coa · /pdf/tirzepatide.pdf

FAT LOSS

Tirzepatide

GIP / GLP-1 Dual Agonist

Dual GIP and GLP-1 receptor agonist. Superior fat-loss profile to semaglutide in head-to-head.

MECHANISM	DOSAGE	HALF-LIFE	FORMAT
Dual GIP / GLP-1 receptor agonist	2.5–15 mg once weekly SC	~5 days	Lyophilised powder

BATCH	LOT	CAS	FORMULA	ISSUED	RETEST
NU-TIR-8687	440687	2023788-19-2	C225H348N48O…	2025-10-06	2026-10-06

OVERVIEW

Tirzepatide is a dual agonist co-activating both GIP and GLP-1 receptors via a single molecule. The additive effect of GIP stimulation produces superior weight loss to semaglutide. The SURMOUNT-1 trial reported up to 22.5% mean bodyweight reduction at 15 mg weekly, establishing tirzepatide as the leading dual agonist.

MECHANISM OF ACTION

Dual GIP / GLP-1 receptor agonist

KEY RESEARCH BENEFITS

- Up to 22.5% bodyweight reduction in SURMOUNT-1
- Superior to semaglutide in head-to-head (SURPASS-2)
- Potent HbA1c reduction in T2D research
- Improves lipid profiles and blood pressure
- GIP component may reduce GI side-effect burden

RESEARCH NOTES

SURMOUNT-1 (N = 2,539) showed 15.0–22.5% weight loss vs 2.4% placebo at 72 weeks. SURPASS-2 demonstrated superiority over semaglutide 1 mg across all endpoints.

STORAGE & STABILITY

Lyophilised: -20 °C, stable >=24 months. Reconstituted: 2–8 °C, use within 28 days.

THIRD-PARTY HPLC VERIFIED

Janoshik Analytics · Freedom Diagnostics

new-u.io · hello@new-u.io